Home > Boards > US Listed > Biotechs >

Invitae Corp. (NVTA)

Add NVTA Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 1/12/2018 2:08:02 PM - Followers: 8 - Board type: Free - Posts Today: 0

Genetics is the future of medicine.

Our vision.

Invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people.

Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today.

What’s our plan? It takes three steps:

Make genetic testing more affordable and accessible than ever before.
Build a secure and trusted genome management infrastructure.
Design a new global community for sharing genetic information to advance science and medicine.
Today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. Together we can improve healthcare for billions of people.
Making genetic testing affordable and accessible.

Today, Invitae can deliver results for any genetic test in our catalog for $1,500 in an average of three weeks.

As a part of that catalog, the company currently offers the following panels:

Featured cancer panels

BRCA1 and BRCA2, including full gene sequencing and deletion/duplication analysis
Hereditary breast cancer, high-risk panel (7 genes)
Hereditary breast cancer, extended panel (12 genes)
Women’s hereditary cancer panel (18 genes associated with hereditary breast, ovarian and endometrial cancer)
Lynch syndrome (5 genes)
Hereditary colon cancer, high-risk panel(7 genes)
Hereditary colon cancer (14 genes)
Hereditary pancreatic cancer (17 genes)
Hereditary cancer syndromes panel (29 genes)
Featured cardiology panels

Brugada syndrome (10 genes)
Long QT syndrome (13 genes)
Hypertrophic cardiomyopathy (16 genes)
Short QT syndrome (6 genes)
Featured neurology panels

Charcot-Marie Tooth disease (28 genes)
Hereditary spastic paraplegia (17 genes)
Additionally, Invitae is committed to improving family health by leveraging the power of genetic information and innovative technologies. The “Invitae Family History Tool” is the first free family history collection app that enables genetic counselors to digitally build, modify, share, and save their patients’ pedigrees.

Learn more about the Family History Tool.
An unparalleled team.

Invitae has assembled a team of more than 130 of the world’s foremost experts in genetics, bioinformatics, engineering, technology, and commercial development, among other disciplines. The company was founded in 2012 by CEO Randy Scott (co-founder of Genomic Health [Nasdaq: GHDX] and Incyte [Nasdaq: INCY]) through an investment in Locus Development, founded by Sean George, Michele Cargill, Alex Furman and Mat Falkowski.

Since its inception, Invitae has collectively raised $207 million.
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NVTA News: Invitae more than doubles annual volume, exceeds full-year 2017 guidance, and projects momentum to continue in 2018 01/08/2018 07:30:00 AM
NVTA News: Invitae to present at the 36th Annual J.P. Morgan Healthcare Conference 12/20/2017 07:30:00 AM
NVTA News: Multigene Genetic Testing Improves Identification and Management of Hereditary Cancer Risk for Breast Cancer Patients and The... 12/05/2017 07:30:00 AM
NVTA News: Statement of Ownership (sc 13g) 12/01/2017 05:05:16 PM
NVTA News: Current Report Filing (8-k) 11/15/2017 07:49:53 AM
#26   In @ $7.80 on a major sell-off this chmcnfunds 01/12/18 02:08:02 PM
#25   With our potential for growth; shub 09/12/17 02:58:32 PM
#24   Looking like buildup of very desirable AI gene x1power 09/07/17 11:54:51 AM
#23   Looks like we are acquiring 2 smaller genetics shub 08/01/17 01:43:42 PM
#22   "ASCO Data Shows Prostate Cancer Patients with Genetic shub 06/05/17 03:54:14 PM
#21   Wow! "Invitae Exceeds 26,000 Samples Accessioned". Thats 166% more shub 05/09/17 03:04:51 PM
#20   We keep expanding our offerings at a brisk shub 03/23/17 01:23:08 PM
#19   Up to 10.30 and about to present 17 shub 03/15/17 04:12:42 PM
#18   9.83 just now...Buncha upgrades and very impressive growth shub 02/14/17 02:42:55 PM
#17   Pre market over 10.50. Probably drop some Matrix999 02/14/17 08:58:03 AM
#16   Well, RE the PPS, that seems to be shub 02/13/17 02:45:34 PM
#15   This puppy is roaring! shub 01/09/17 03:35:19 PM
#14   NVTA bearish 7.35 stocktrademan 11/26/16 07:12:14 PM
#13   Brigar: Making a stock decision based on a message shub 09/13/16 03:48:38 PM
#12   The story seems tasty and the services seem shub 09/01/16 02:25:21 PM
#11   NVTA bearish 7.86 stocktrademan 06/17/16 12:52:20 PM
#10   Chart been rallying, any thoughts on continuation into Christie Mensch 11/29/15 07:35:18 PM
#9   10-Q Cash $68M O/S 31.8M RealGenius 05/17/15 08:44:40 PM
#8   a "friend" in the industry telling you inside brigar6 04/23/15 08:32:47 AM
#7   Buy now before its too late !!!!!!! I billionaire19865 04/17/15 03:05:59 PM
#6   NVTA I thought this IPO would draw a MR. McBALL$ 02/12/15 06:50:16 PM
#5   When is the IPO expected issued on tpizzazz24 01/17/15 09:22:36 PM
#4 MR. McBALL$ 01/12/15 12:46:01 PM
#3   Blackrock has $50 M in this one. RealGenius 01/11/15 02:34:13 PM
#2   Baker Brothers Life Sciences has $50M in this one. RealGenius 01/11/15 02:33:51 PM
#1 MR. McBALL$ 01/09/15 06:07:51 PM